• Collaborators
  • Publications
OncoSpherix
  • Home
  • About
  • Science
  • Clinical Targets
  • News & Events
Select Page

OncoSpherix Named Finalist for 2025 BIO International Convention Start-Up Stadium

by Oncospherix | May 13, 2025 | General

May 13, 2025 Emerging oncology innovator OncoSpherix to showcase breakthrough cancer therapies at global biotech stage in Boston Atlanta, GA — May 2025 — OncoSpherix, a pre-clinical-stage oncology company advancing novel therapies for unresectable and metastatic...

OncoSpherix Selected to Present at Portal Innovations’ ‘Rising Stars in Oncology’ Event During AACR 2025

by Oncospherix | Apr 22, 2025 | General

April 22, 2024 OncoSpherix to Showcase Breakthrough Oncology Innovations at Premier Biotech Event Atlanta, GA – Apr 2025 – OncoSpherix, a biotech company pioneering innovative therapies for tumor hypoxia, is excited to announce its participation in Portal Innovations’...

OncoSpherix Relocates to Portal Innovations’ State-of-the-Art Life Sciences Facilities, Poised for Next Stage of Growth

by Oncospherix | Nov 20, 2024 | General

November 20, 2024 OncoSpherix Becomes a Portal Innovations Member Company Atlanta, GA – Nov 2023 – OncoSpherix,, Inc., a preclinical-stage cancer drug development company advancing HIF inhibitors for a variety of cancer indications, is excited to announce its recent...

OncoSpherix Showcased at 2024 Georgia Bio Life Sciences Summit, Highlights Latest Advances in Cancer treatment

by Oncospherix | Nov 18, 2024 | General

November 18, 2024 OncoSpherix Participates in Annual Georgia Life Sciences Summit Atlanta, GA – Nov 18, 2024 – OncoSpherix, Inc., a preclinical-stage cancer drug development company advancing HIF inhibitors for a variety of cancer indications, proudly participated in...

OncoSpherix expands its operations team with the appointment of Joseph Ellis, Ph.D., as Research Scientist

by Oncospherix | Oct 1, 2024 | General

Oct 1, 2024 Joseph Ellis, Ph.D., joins OncoSpherix’s Research Team Atlanta, GA – Oct 1, 2024 – OncoSpherix, Inc., a preclinical-stage cancer drug development company advancing HIF inhibitors in variety of cancer indications, announces the appointment of Joseph Ellis,...
« Older Entries

Get Involved

  • Collaborators
  • Publications

Contact us

Contact@OncoSpherix.com

2021 All Rights Reserved